Market Place
Sourcing Support
Kura Oncology Reports Preclinical Data For Ziftomenib In GIST
24 Oct 2024 //
GLOBENEWSWIRE
Kura Oncology Publishes Ziftomenib Ph 1 Results In The Lancet
30 Sep 2024 //
GLOBENEWSWIRE
Kura Oncology Announces FDA Clearance Of IND For Ziftomenib In GIST
08 Aug 2024 //
GLOBENEWSWIRE
Kura Reports Preclinical Data on Menin Inhibitor`s Potential in Diabetes
24 Jun 2024 //
GLOBENEWSWIRE
Kura Completes Ziftomenib NPM1-Mutant AML Trial Enrollment
14 May 2024 //
GLOBENEWSWIRE
Kura Oncology Reports First Quarter 2024 Financial Results
02 May 2024 //
GLOBENEWSWIRE
Kura Gets Ziftomenib BTD In NPM1-Mutant AML
22 Apr 2024 //
GLOBENEWSWIRE
Kura Doses First Patient in KOMET-008 Trial of Ziftomenib with Standards of Care
26 Feb 2024 //
GLOBENEWSWIRE
Kura Reports Positive Ziftomenib Combination Data in Acute Myeloid Leukemia
30 Jan 2024 //
GLOBENEWSWIRE
Kura Oncology™s Menin Inhibitor Ziftomenib Selected for PedAL Trial
08 Dec 2023 //
GLOBENEWSWIRE
Kura Oncology Presents Late-Breaking Data for Menin Inhibitor Ziftomenib
11 Jun 2023 //
GLOBENEWSWIRE
Kura Oncology Reports First Quarter 2023 Financial Results
10 May 2023 //
GLOBENEWSWIRE
Kura Oncology Presents Updated Clinical Data from KOMET-001 Trial
10 Dec 2022 //
GLOBENEWSWIRE
Copyright © 2024 LePro PharmaCompass OPC Private Limited, All rights reserved.